National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Cancer Screening Overview (PDQ®)
Health Professional VersionLast Modified: 11/06/2009



Cancer Screening






Get More Information From NCI







Changes To This Summary (11/06/2009)






Questions or Comments About This Summary






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Changes To This Summary (11/06/2009)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Cancer Screening

Added text to state that a 2009 publication of preliminary results of a cancer screening project in Japan using multiple whole-body screening technologies illustrates clearly the problems of false-positive screening results and potential overdiagnosis (cited Nishizawa et al. as reference 3).

Added text about a project in Japan that enrolled 1,217 healthy volunteers aged 35 years and older for health check-ups, including chest x-ray, fecal occult blood testing, upper gastrointestinal series, and mammography screening for many years.

Added text to state that all participants were offered annual whole body screening by fluorodeoxyglucose positron emission tomography, chest and abdominal computed tomography, brain and pelvic magnetic resonance imaging, analyses of serum tumor markers including carcinoembryonic antigen, cancer antigen 19-9, squamous cell carcinoma antigen, prostate specific antigen for men older than aged 50 years, cancer antigen 125 for women, and FOB testing.

Added text to state that a screen was classified positive if any test was suggestive of malignancy, and in these cases the subject was referred to a local hospital for further testing or retesting at the screening center; therefore interval cancer events were ascertained at subsequent screenings or by interview.

Added text to state that 22 primary cancers were pathologically confirmed, 19 by annual screening, and 18 at the initial screen.

Added text to state that the incidence of cancers found on the initial screen exceeded the estimated age-matched annual incidence of cancer in Japan by three to four times.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov